Direct emissions
112
tCO2e
Back to search resultsEmissions
Sustainability
Scope
REPORTED REPORTED REPORTED ESTIMATED ESTIMATED REPORTED ESTIMATED REPORTED REPORTED ESTIMATED ESTIMATED ESTIMATED ESTIMATED ESTIMATED ESTIMATED ESTIMATED ESTIMATED 
Read the full scoring methodologyOur white paper covers exactly how the Mycelium Score and Transparency Score are calculated, including the normalisation process and what earns a 10/10.Download the white paper (PDF)
Mycelium Score5.5 / 10A mid-pack scoreATransparencyVery HighExtensive disclosure across almost all key areas
Explore carbon emissions data for CHEPLAPHARM SE. Mycelium helps you review reported emissions, disclosure status, Scope 1, Scope 2 and Scope 3 data, climate targets and sustainability information in one company profile.
This profile brings together available carbon emissions data for CHEPLAPHARM SE, including reported figures, modelled estimates, disclosure documents and sustainability indicators, so you can review its emissions and compare its performance against similar companies. It is one entry in the Mycelium emissions database. Read how we source and check this data.
Emissions
Carbon emissions
Total yearly emissions across all scopes
412,689tCO2e(Market Based)(Mycelium adjusted)
- Reported by CHEPLAPHARM SE
- 362,355 tCO₂e
- Estimated by Mycelium
- 50,334 tCO₂e
CHEPLAPHARM SE reported 88% of the adjusted total. Mycelium estimated the remaining 12% for the categories it did not disclose.
Scope 1
tCO2e
112
Scope 2 (Market Based)
tCO2e
3
Scope 3 total
tCO2e
412,574
Figures from page 17 of the source report
Scope 3 reported
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
Something wrong? Contribute to this dataset
See the scope breakdownProvenance
Emissions
Factors
0.229kgCO2e / $
Supplier specific emission factors (kgCO2e / $)
Modelled
Reported
UpstreamScope 1, 2 + upstream Scope 3
0.229
0.218
Total+ all Scope 3
–
0.218
Per US dollar of revenue. Mycelium models the upstream factor only.
Which figure should I use?
Estimating your own supply-chain emissions from spend with this company? Use Upstream Modelled. The GHG Protocol defines purchased-goods emissions as cradle-to-gate, which means this company's own operations plus its upstream supply chain. Any of those emissions the company has not disclosed are filled with modelled estimates, so a transparent company is not unfairly penalised against one that simply has not reported.
Looking at what the company filed itself? Use the Reported column. Total Reported also includes downstream emissions, such as the lifetime use of the products this company sells, which the GHG Protocol attributes to the users of those products rather than to customers buying goods and services.
Reported counts only emissions the company has filed itself. A blank or low Reported cell does not mean those emissions do not exist, just that the company has not disclosed them. When Upstream Reported sits close to Upstream Modelled, that is a positive signal: the company has disclosed most of its upstream emissions.
Sustainability
Snapshot
Based on reported data, retrieved with AI
- CHEPLAPHARM SE reported 362,355 tCO₂e in 2024.
- Scope 3 accounted for 100% of reported emissions.
- Reported across 4 of 15 GHG Protocol Scope 3 categories.
- Scope 2 reported under the market based methodology.
According to available emissions disclosures, CHEPLAPHARM SE reported total yearly emissions of 362,355 tCO₂e in 2024. Scope 3 emissions accounted for 100% of the reported footprint, indicating supply chain activity, purchased goods and services, business travel, and wider operational dependencies were the most significant contributors to the company's carbon footprint.
The company achieved a Mycelium Score of 5.5, placing it mid-pack within its sector for sustainability performance, and received a transparency score of 93.1, an exceptional result, reflecting open disclosure across nearly every key emissions metric.
Scope
breakdown
Scope 1 emissions
Direct emissions from sources the company owns or controls, such as fuel use, facilities and vehicles.
Scope 2 emissions
Indirect emissions from purchased energy, including electricity, heating and cooling.
Location based
–
tCO2eMarket based
3
tCO2eScope 3 emissions
Wider value chain emissions across the 15 GHG Protocol categories, from purchased goods and business travel to investments, where reported.
Cat 1
Purchased goods & services
354,171
tCO2eCat 2
Capital goods
10,327
tCO2eCat 3
Fuel & energy related activities
8,052
tCO2eCat 4
Upstream transportation & distribution
7,195
tCO2eCat 5
Waste generated in operations
226
tCO2eCat 6
Business travel
590
tCO2eCat 7
Employee commuting
284
tCO2eCat 8
Upstream leased assets
582
tCO2eCat 9
Downstream transportation & distribution
1,505
tCO2eCat 10
Processing of sold products
2,021
tCO2eCat 11
Use of sold products
17,851
tCO2eCat 12
End-of-life treatment of sold products
2,563
tCO2eCat 13
Downstream leased assets
866
tCO2eCat 14
Franchises
5,635
tCO2eCat 15
Investments
706
tCO2e11 values were derived via Mycelium's normalisation process rather than reported by the company. A cell marked “ESTIMATED” is a figure the company did not disclose, modelled by Mycelium.
Contact Info
Website
cheplapharm.comCountry
Germany
Browse carbon emissions data by industry
Jump straight into the sectors users explore most, or view all industries.
How scoring works
How the Mycelium Score is calculated
The Mycelium Score is out of 10. Up to 6.5 points reflect carbon intensity vs peers in the same NACE section (emissions normalised against revenue, log-scaled between the 5th and 95th percentile of each company's latest reporting year in that section; a section needs at least 5 companies to be benchmarked). The band above 6.5 is earned through verified data quality on a claimed profile: declaring every reporting category yourself (up to 2.0), preparation by a carbon accountant (2.0) and independently audited figures (2.0). The total is multiplied by the transparency score and capped at 10. A disclosure with an implausibly large figure (Scope 1 or 2 over 300 million tonnes, a Scope 3 figure over 2 billion tonnes or a total over 2.5 billion tonnes) is not scored until it has been checked.
A higher score means lower carbon intensity than sector peers, backed by data that's third-party verified, claimed by the company, and fully disclosed. CHEPLAPHARM SE's score sits at the top of this page and in the score panel. Without a revenue figure to measure carbon intensity, or an industry classification to compare it within, a company has no score.
How the Transparency Score is calculated
The Transparency Score is the share of a company's estimated footprint that it reported itself, graded from A (very high) down to F (very low). Where a category is missing, Mycelium models what it would hold for a company of that size and industry and counts it as undisclosed, so an unreported category where the bulk of emissions sit hurts far more than a minor one. Unreported downstream categories (9 to 15) count at a quarter of their modelled size in this share; the carbon intensity behind the score still counts them in full. A Scope 3 total filed without a category breakdown earns very little credit for the part left unattributed, because it does not show which categories are inside it: a company can count business travel, leave purchased goods out entirely, and the total looks the same. Without a revenue figure the footprint cannot be modelled, so the company has no Transparency Score.
For CHEPLAPHARM SE, the single biggest gap is Use of sold products (Scope 3 Category 11). Mycelium estimates it accounts for around 4% of the company's estimated footprint, yet it hasn't been disclosed. Leaving a bucket this large unreported is what's holding the transparency score down.
In total, roughly 12% of CHEPLAPHARM SE's estimated emissions sit in categories it hasn't reported. Disclosing these would be the fastest way to raise the transparency score.
Read the full scoring methodologyOur white paper covers exactly how the Mycelium Score and Transparency Score are calculated, including the normalisation process and what earns a 10/10.Download the white paper (PDF)Compare CHEPLAPHARM SE with similar companies
CHEPLAPHARM SE carbon emissions FAQs
What are CHEPLAPHARM SE's carbon emissions?
In its 2024 reporting year, CHEPLAPHARM SE disclosed total emissions of 362,355 tCO2e across all scopes. Including Mycelium estimates for undisclosed categories, the adjusted total is 412,689 tCO2e. Scope 3 accounted for the largest share of the reported total, around 100%.
Does CHEPLAPHARM SE report Scope 1, Scope 2 and Scope 3 emissions?
For 2024, CHEPLAPHARM SE's available disclosure covers Scope 1 (112 tCO2e), Scope 2 (3 tCO2e) and Scope 3 across 4 of the 15 GHG Protocol categories. Figures not reported by the company are shown as modelled estimates and labelled as such.
How transparent is CHEPLAPHARM SE's emissions reporting?
CHEPLAPHARM SE has a Mycelium transparency score of 93.1 out of 100. The score is the share of the company's estimated footprint that it reported itself, so an undisclosed category where most of its emissions sit weighs far more than a minor one.
Is CHEPLAPHARM SE sustainable?
Mycelium measures sustainability through carbon emissions data rather than giving a yes or no verdict. CHEPLAPHARM SE has a Mycelium Score of 5.5 out of 10, which reflects its emissions intensity against sector peers together with how transparent and well-verified its reporting is. The emissions figures and disclosure documents on this page give the fuller picture.
Is CHEPLAPHARM SE environmentally friendly?
Carbon emissions are one measurable part of environmental impact, and the part Mycelium tracks. CHEPLAPHARM SE disclosed 362,355 tCO2e for 2024, and its Mycelium Score of 5.5 out of 10 shows how that performance compares with similar companies in its sector.
Learn more about our methodology and where this data comes from.